Salute e Benessere
GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion | DelveInsight
Discover which indication is expected to grab the major GPCR-targeting therapies market share @
The GPCR-targeting therapies market is experiencing dynamic growth, driven by , an , and the in a wide array of diseases. GPCRs represent the largest family of membrane receptors in humans and are involved in regulating various physiological processes, making them attractive targets for drug development. Approximately of currently approved drugs act on GPCRs, underscoring their clinical and commercial significance.
One of the key market dynamics is the such as cardiovascular diseases and neurological disorders. has highlighted the role of GPCRs in oncology, metabolic disorders, and immune-mediated diseases, fueling interest in developing novel ligands, biased agonists, and allosteric modulators that offer greater specificity and reduced side effects. The and using cryo-electron microscopy have further enabled the design of highly targeted therapies.
Pharmaceutical companies are increasingly , often in collaboration with biotechnology firms and academic research institutions. are common, aiming to access novel chemistries and platform technologies, such as structure-based drug design, high-throughput screening, and artificial intelligence-enabled ligand discovery. These collaborations are vital for accelerating R&D timelines and reducing attrition rates in clinical development.
However, the market also faces several challenges, including the . for patient stratification further complicate commercialization efforts. Despite these barriers, the pipeline remains robust, with a growing number of GPCR-targeting candidates advancing through preclinical and clinical stages.
Overall, the GPCR-targeting therapies market is poised for sustained expansion, supported by of GPCRs. With the convergence of computational biology, structural pharmacology, and translational research, the next wave of GPCR-targeting drugs is expected to offer novel mechanisms of action and improved patient outcomes across diverse indications.
The market outlook for GPCR-targeting therapies is promising, driven by successful drugs like . is an innovative small-molecule antagonist of the CGRP receptor, approved for the acute treatment of migraines, both with and without aura, in adults. It works by inhibiting the CGRP receptor, which plays a key role in migraine development by contributing to neurogenic inflammation and blood vessel dilation. Administered as a nasal spray, ZAVZPRET allows for quick absorption through the nasal lining, providing direct access to the bloodstream while bypassing the digestive system and first-pass liver metabolism.
, developed by , is a humanized monoclonal antibody that targets the CCR4 receptor—a protein commonly found on certain cancerous T-cells. By binding to CCR4, the drug helps recruit immune cells to attack and eliminate malignant cells, thereby boosting the body's immune defense against cancer. Initially approved in Japan in 2012 for relapsed or refractory CCR4-positive adult T-cell leukemia (ATL), its indication was expanded in 2014 to include relapsed or refractory CCR4-positive peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). The U.S. FDA approved POTELIGEO in 2018 for Mycosis Fungoides and Sézary Syndrome, with similar approvals granted in Europe . In June 2020 , the drug became commercially available in Germany for adults with Mycosis Fungoides or Sézary Syndrome who had undergone at least one prior systemic treatment.
, co-developed by , is a fully human monoclonal antibody that selectively binds to and blocks CGRP receptors. CGRP ligands, which are small neuropeptides, contribute to migraine and chronic pain through strong vasodilatory effects. By directly competing with CGRP, erenumab provides a high degree of specificity and effectiveness compared to small-molecule therapies. It is used to treat conditions such as migraine, vasoconstriction, hot flashes, and stable angina pectoris. The antibody received approval in the U.S. in May 2018 and in the EU in July 2018 .
Learn more about the FDA-approved GPCR-targeting therapies @
Several key players, including (Leronlimab), (Volagidemab), (GSBR-1290), (GPC-100), and others, are involved in developing drugs for GPCR-targeting therapies for various indications such as NASH, Multiple Myeloma, Diabetes, and others.
is a human monoclonal antibody targeting the glucagon receptor (GCGR), developed by REMD Biotherapeutics for the treatment of juvenile type I diabetes (T1D) and type II diabetes (T2D). It functions by binding to GCGR and competitively inhibiting its signaling pathway. This action enhances glucose uptake by the liver, reduces the breakdown of glycogen and gluconeogenesis, and stimulates glycogen synthesis—collectively contributing to its blood sugar-lowering effects (CK060182). As of March 2021 , the drug was being investigated in multiple indications: T1D and T2D were in Phase II clinical trials, glucose intolerance was in Phase I, and metabolic disorders were in the preclinical stage (CK060183).
is classified as a viral entry inhibitor, a type of HIV therapy that blocks the virus from penetrating and infecting healthy cells. In contrast to Highly Active Antiretroviral Therapy (HAART), which targets HIV after cell entry and replication, Leronlimab intervenes earlier in the viral life cycle. The critical role of the CCR5 receptor in HIV infection is highlighted by the natural immunity observed in individuals with a genetic mutation that disables CCR5 expression. Leronlimab is currently under development for the treatment of Nonalcoholic Steatohepatitis (NASH), HIV-associated NASH, and various solid tumors, with development efforts currently in Phase II.
In April 2019 , the company signed multiple agreements with Samsung for the transfer of technology, process validation, manufacturing, and pre-approval inspection services, aimed at supporting the commercial production of Leronlimab's bulk drug substance.
The anticipated launch of these emerging therapies are poised to transform the GPCR-targeting therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GPCR-targeting therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about GPCR-targeting therapies clinical trials, visit @
G protein-coupled receptors (GPCRs) are a vital group of cell surface receptors that regulate numerous physiological processes. In many cancers, GPCR pathways are often dysregulated due to abnormal expression, increased activity, or mutations, contributing to uncontrolled cell growth, blood vessel formation, and metastasis. GPCRs are categorized into several classes based on their structure and function. In humans, the primary classes include Class A (Rhodopsin-like), Class B (Secretin and Adhesion), Class C (Metabotropic glutamate/pheromone), and Class F (Frizzled/TAS2).
Additional classes, such as Class D (fungal mating pheromone receptors) and Class E (cyclic AMP receptors), are present in non-human organisms. Among these, Class A is the most extensive, encompassing a majority of hormone, neurotransmitter, and sensory receptors. Class B is split into secretin and adhesion subgroups, Class C comprises receptors for glutamate and GABA, and Class F includes receptors like frizzled and smoothened involved in Wnt signaling. This classification underscores the structural and functional diversity of GPCRs and their critical roles in both normal physiology and disease.
The GPCR-targeting therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Discover more about GPCR-targeting therapies in development @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key migraine companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTCL companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PTCL companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/gpcr-targeting-therapies-market-poised-for-strong-growth-during-the-forecast-period-20252034-across-7mm-due-to-the-rising-cancer-diagnoses-and-drug-pipeline-expansion--delveinsight-302494131.html